
    
      In this study, eligible subjects will be randomized into study arm or control arm.
      Participants receive camrelizumab or placebo + chemotherapy + radiation therapy . The
      chemotherapy regimens are : paclitaxel plus cisplatin Progression-free survival (PFS)
      assessed by the Independent Review Committee (IRC) will be the primary outcomes.
    
  